Skip to Main content Skip to Navigation
New interface
Journal articles

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-02299505
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Wednesday, July 20, 2022 - 2:28:34 PM
Last modification on : Thursday, July 21, 2022 - 3:27:07 AM
Long-term archiving on: : Friday, October 21, 2022 - 8:13:31 PM

File

S2352302619301139.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Collections

Citation

Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, Valérie Rouillé, Béatrice Mahé, et al.. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. The Lancet Haematology, 2019, 6 (9), pp.e470-e479. ⟨10.1016/S2352-3026(19)30113-9⟩. ⟨hal-02299505⟩

Share

Metrics

Record views

43

Files downloads

12